Shenzhen Geno-Immune Institute (SGIMI) Initiates Phase 1 Clinical Trial for YUVA-GT-F901, a Lentiviral Gene Therapy for Hemophilia B
A New Generation of Hemophilia B Treatment Options Emerges
The Phase 1 clinical trial of YUVA-GT-F901, developed by Shenzhen Geno-Immune Medical Institute, marks a significant step towards a new treatment paradigm. Currently, patients with Hemophilia B face the burden of lifelong, expensive protein injections to supplement their deficient Factor IX. This trial aims to achieve a permanent therapeutic effect through a single administration by genetically modifying and transplanting autologous hematopoietic stem cells ex vivo.
Technological Differentiation of Lentiviral Vectors
Unlike existing therapies that utilize adeno-associated virus (AAV) vectors, this therapy employs a lentiviral vector. Existing therapies, such as Hemgenix, have a clear limitation: administration is impossible if patients have pre-existing AAV neutralizing antibodies. In contrast, YUVA-GT-F901 uses an ex vivo approach, genetically modifying cells outside the body before transplantation, which completely bypasses the neutralizing antibody immune response. Furthermore, because it is directly and permanently inserted into the host genome, it demonstrates a long duration of action, even in pediatric patients whose cells continue to divide.
Reshaping the Global Gene Therapy Market
The global Hemophilia B market is currently valued at approximately $2.96 billion in 2024, with the gene therapy segment growing rapidly at over 23% annually. The initiation of this Phase 1 trial demonstrates the independent competitiveness of Asian technology in a market dominated by global leaders such as Pfizer's Beqvez and uniQure. If the trial is successful, it will provide Asian patients with an affordable, domestically produced treatment option, potentially reshaping the market currently dominated by high-priced multinational pharmaceutical companies.
Long-Term Safety Validation and Future Challenges
Of course, YUVA-GT-F901 is still in the early stages, and demonstrating long-term safety is the biggest challenge before final approval. The risk of insertional mutagenesis and potential carcinogenicity due to random integration of the lentiviral vector into the genome must be carefully monitored. If the initial Phase 1 trial can demonstrate clear safety data and sufficient Factor IX expression levels, it will secure tremendous business value as a next-generation cell and gene therapy platform.
Shenzhen Geno-Immune's YUVA-GT-F901, in its Phase 1 stage, presents a novel alternative by combining autologous hematopoietic stem cells with lentiviral vectors to overcome the antibody-mediated immune response limitations of existing adeno-associated virus (AAV) vectors. This creates a commercial opportunity to capture patients who are ineligible for existing, commercially available, single-dose AAV-based therapies like uniQure's Hemgenix or Pfizer's Beqvez. In the Hemophilia B market, which is expected to grow from $2.96 billion in 2024 to a maximum of $5.94 billion in the gene therapy sector by 2032, this differentiated ex vivo treatment strategy will initially attract investor interest due to its technological novelty. In the medium to long term, targeting the Chinese and Asian markets, it has the potential to significantly reduce the extremely high price of current U.S. gene therapies (around $3.5 million) and expand access, thereby reshaping the market. For researchers and developers in the field of gene therapy, it will serve as a significant milestone in demonstrating the effectiveness of lentiviral insertion technology in ensuring long-term expression and preventing gene loss in dividing cells, particularly in pediatric patients.
Source: ClinicalTrials.gov (api_ct)